electroCore, Inc. represents a strong commitment to improving patient outcomes and quality of life. Their corporate philosophy revolves around innovation, cutting-edge technology, and evidence-based solutions. By leveraging their expertise in bioelectronic medicine and neurostimulation, electroCore strives to empower healthcare professionals and patients with non-invasive treatment options. With a focus on patient-centricity, electroCore aims to enhance healthcare accessibility and deliver personalized therapies for neurologic, respiratory, and other complex conditions. By continuously pushing boundaries and fostering collaborations, electroCore sets high standards in delivering advanced medical solutions backed by scientific rigor and clinical research.

electroCore, Inc. is primarily present in the United States, European Union, Canada, and Australia.

Some significant milestones achieved by electroCore, Inc. include the FDA approval of their non-invasive vagus nerve stimulation therapy for the treatment of cluster headaches in 2017. The company also received CE Mark approval in Europe for their gammaCore therapy in 2013, expanding their market reach. Additionally, electroCore has entered into numerous collaborations and partnerships with major healthcare organizations and institutions to further develop and commercialize their innovative therapies. These milestones demonstrate electroCore's commitment to advancing healthcare through their cutting-edge treatments and expanding global accessibility to their products.

electroCore, Inc. is a leading bioelectronic medicine company founded in 2005. With a strong focus on developing non-invasive vagus nerve stimulation (nVNS) therapies, electroCore aims to provide innovative solutions for a variety of healthcare conditions. The company utilizes its proprietary gammaCore™ system, a portable and easy-to-use device, approved by the FDA for the acute treatment of pain associated with cluster headache and migraine. electroCore continues to expand its portfolio by exploring potential applications in various neurological and neuropsychiatric disorders. With a commitment to improving patient outcomes and quality of life, electroCore has emerged as a pioneering player in the field of bioelectronic medicine.

The main competitors of electroCore, Inc. in the market include companies such as BioElectronics Corporation and CEFALY Technology.

electroCore, Inc. is primarily active in the healthcare industry. As a medical technology company, electroCore specializes in non-invasive neuromodulation therapies. They specifically focus on the treatment of neurological and inflammatory conditions. With their innovative devices and therapies, electroCore aims to improve patient outcomes and quality of life. By leveraging cutting-edge technology, electroCore is revolutionizing the healthcare landscape and addressing unmet medical needs.

The business model of electroCore, Inc. revolves around developing and commercializing bioelectronic medicine. It focuses on creating innovative medical devices that utilize non-invasive vagus nerve stimulation (nVNS) therapy. By delivering gentle electrical stimulation to the vagus nerve, electroCore aims to treat various healthcare conditions, including cluster headaches and migraines. The company's products, such as gammaCore™, help patients manage and alleviate symptoms by activating the body's natural mechanisms. electroCore, Inc. is committed to advancing the field of bioelectronic medicine and improving the lives of individuals suffering from neurologic and inflammatory conditions.

مُعامل القيمة السوقية إلى الأرباح لـ electroCore, هو ؜-٤٫٤٨.

مُعامِل القيمة إلى المبيعات electroCore, هو ١٫٦٩.

نقاط جودة AlleAktien لـ electroCore, هي 3/10.

المتوقعة electroCore, الإيرادات هي ٢٥٫٦٦ مليون. USD.

صافي الربح المتوقعة electroCore, هو ؜-٩٫٦٩ مليون. USD.

ElectroCore, Inc. is a leading, innovative company specializing in the research, development, and marketing of non-invasive vagus nerve stimulators. The company is based in Basking Ridge, New Jersey, USA and is listed on the NASDAQ under the ticker symbol "ECOR." ElectroCore, Inc.'s products focus on the treatment of neuromuscular and epileptic disorders, as well as the relief of migraine pain. The company develops and markets two types of vagus nerve stimulators, the gammaCore system and the nVNS system. The gammaCore system is a portable device used for the acute treatment of pain from migraines and cluster headaches. The patient places the device on the side of their neck and initiates stimulation with a button press. GammaCore stimulation stimulates the vagus nerve, regulates blood flow in the brain, and reduces pain. The nVNS system from electroCore, Inc. is used for the treatment of epilepsy and neuromuscular disorders. The device consists of a small vagus nerve stimulator that is placed on the patient's neck. The device stimulates the vagus nerve, promoting the release of neurotransmitters that can reduce pain and inflammation. ElectroCore, Inc. also has a comprehensive pipeline product, with neuromodulatory therapy options for the treatment of asthma, COPD, migraines, cluster headaches, neurological disorders, and even psychiatric conditions. The business model of electroCore, Inc. primarily involves the development and marketing of innovative medical devices that improve the health and well-being of patients worldwide. The company has partnerships with medical device representatives and facilities around the world and also operates its own sales and marketing department. ElectroCore, Inc. focuses on a specific target audience, including leading medical professionals and specialists in the field of neurology. The company specializes in marketing its products to hospitals, clinics, and other medical facilities. Given the success of electroCore, Inc.'s board of directors, its leadership qualities, and innovative products, the company is considered one of the most promising in the medical market. It can be expected that electroCore, Inc. will continue to develop groundbreaking products in the future, taking non-invasive medical technology to a whole new level.

يوزع electroCore, أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ electroCore, في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـelectroCore, هو US28531P1030.

رمز WKN لـ electroCore, هو A2N6KT.

الرمز المُختصر لـ electroCore, هو ECOR.

خلال آخر 12 شهراً، دفعت electroCore, توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع electroCore, خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ electroCore, هي .

electroCore, يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

electroCore, دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

electroCore, يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من electroCore, المُعلن عنها في ١٠‏/١٠‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١٠‏/١٠‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١٠‏/١٠‏/٢٠٢٤.

في العام 2023، وزعت electroCore, 0 USD كأرباح أسهم.

يتم توزيع أرباح electroCore, بالعملة USD.